Tearsheet
Investment Highlights Market Valuation Price Chart Return vs. Risk About BMY Interactive Breakdown Better Bets vs. BMY Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Bristol-Myers Squibb (BMY)

Market Price (10/25/2025): $43.75 | Market Cap: $88.9 Bil
Sector: Health Care | Industry: Pharmaceuticals

Bristol-Myers Squibb (BMY)

Market Price (10/25/2025): $43.75
Market Cap: $88.9 Bil
Sector: Health Care
Industry: Pharmaceuticals

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 12%, Dividend Yield is 5.5%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 7.0%, FCF Yield is 15%		 Weak multi-year price returns
2Y Excs Rtn is -75%, 3Y Excs Rtn is -113%		 Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.5%, Rev Chg QQuarterly Revenue Change % is -5.6%
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 30%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 27%, CFO LTM is 14 Bil, FCF LTM is 13 Bil		  
2 Low stock price volatility
Vol 12M is 30%		  
0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 12%, Dividend Yield is 5.5%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 7.0%, FCF Yield is 15%
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 30%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 27%, CFO LTM is 14 Bil, FCF LTM is 13 Bil
2 Low stock price volatility
Vol 12M is 30%
3 Weak multi-year price returns
2Y Excs Rtn is -75%, 3Y Excs Rtn is -113%
4 Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.5%, Rev Chg QQuarterly Revenue Change % is -5.6%

Market Valuation & Key Metrics

BMYS&P 500
REVENUE GROWTH 
Rev LTM ($ Bil)47.6
Rev Chg Q-5.6%6.3%
Rev Chg LTM4.6%5.2%
Rev Chg 3Y Avg0.5%5.3%
PROFITABILITYGOOD
Op Inc LTM ($ Bil)7.9
CFO LTM ($ Bil)14.3
Net Inc LTM ($ Bil)5.4
Op Mgn LTM16.5%18.7%
CFO/Rev LTM30.0%20.4%
Net Inc Mgn11.4%12.7%
VALUATIONLOW
P/S1.93.3
P/CFO6.216.0
P/FCF6.821.0
P/E16.424.1
STABILITYGOOD
Debt/Equity0.580.21
Cash/Assets0.130.07

BMY Stock

   
   
   
   
   
   
   

Return vs. Risk

Price Returns Compared

 202020212022202320242025Total [1]
Returns
BMY Return0%3%19%-26%16%-19%-15%
Peers Return12%25%10%18%1%8%99%
S&P 500 Return16%27%-19%24%23%15%106%

Monthly Win Rates [3]
BMY Win Rate42%42%75%25%67%44% 
Peers Win Rate45%48%47%43%47%51% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
BMY Max Drawdown-27%-12%-1%-30%-20%-21% 
Peers Max Drawdown-18%-6%-14%-8%-9%-15% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: LLY, JNJ, MRK, ZTS, BGM. See BMY Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/24/2025 (YTD)

How Low Can It Go

Unique KeyEventBMYS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-40.2%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven67.3%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-31.2%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven45.3%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven476 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-38.0%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven61.3%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven743 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-46.3%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven86.2%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven1084 days1480 days

Compare to LLY, JNJ, MRK, ZTS, BGM


In The Past

Bristol-Myers Squibb's stock fell -40.2% during the 2022 Inflation Shock from a high on 12/2/2022. A -40.2% loss requires a 67.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Bristol-Myers Squibb (BMY)

Interactive Breakdown

Bristol-Myers Squibb Interactive Breakdown Analysis

Better Bets than Bristol-Myers Squibb (BMY)

 BMYBetter Performance than BMY
MetricValueIndustry (Pharmaceuticals)
Rev Chg LTM4.6%LLY (36.8%), JNJ (5.1%), PFE (13.5%), ZTS (5.3%), CORT (25.7%)
Rev Chg 3Y Avg0.5%LLY (23.4%), JNJ (6.1%), MRK (3.7%), ZTS (5.5%), JAZZ (5.5%)
Op Mgn LTM16.5%LLY (43.0%), JNJ (26.2%), MRK (31.2%), PFE (26.1%), ZTS (37.5%)
CFO/Rev LTM30.0%ZTS (31.2%), JAZZ (32.2%), ALKS (34.6%), INVA (54.2%), SIGA (66.3%)
FCF/Rev LTM27.5%JAZZ (30.3%), ALKS (31.9%), SUPN (27.9%), COLL (28.5%), INVA (53.1%)
Total Yield11.6%PFE (12.8%), OGN (39.0%), AMPH (11.7%), SIGA (13.6%), EBS (26.4%)
 BMYBetter Performance than BMY
MetricValueAll Other Sectors
Rev Chg LTM4.6%NVDA (71.6%), AAPL (6.0%), MSFT (14.9%), GOOGL (13.1%), AMZN (10.9%)
Rev Chg 3Y Avg0.5%NVDA (92.0%), AAPL (1.8%), MSFT (12.5%), GOOGL (10.2%), AMZN (11.3%)
Op Mgn LTM16.5%NVDA (58.1%), AAPL (31.9%), MSFT (45.6%), GOOGL (32.7%), META (42.9%)
CFO/Rev LTM30.0%NVDA (46.6%), MSFT (48.3%), GOOGL (36.0%), META (56.4%), AVGO (42.4%)
FCF/Rev LTM27.5%NVDA (43.6%), META (30.7%), AVGO (41.6%), V (56.8%), MA (49.2%)
Total Yield11.6%BABA (36.1%), TM (2036.8%), VZ (18.0%), TD (15.0%), COP (11.7%)
null

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Bristol-Myers Squibb Earnings Notes  
2How Low Can Bristol-Myers Squibb Stock Really Go?Return 
3Day 8 of Loss Streak for Bristol-Myers Squibb Stock with -6.3% Return (vs. -22% YTD) [9/25/2025]Notification 
4Bristol-Myers Squibb vs Duke Energy: Which Is A Better Investment?Counter-Intuitive Comparisons 
5Bristol-Myers Squibb vs Royalty Pharma: Which Is A Better Investment?Counter-Intuitive Comparisons 
6Bristol-Myers Squibb vs Innoviva: Which Is A Better Investment?Counter-Intuitive Comparisons 
7How Does Bristol-Myers Squibb Stock Stack Up Against Its Peers?Peer Comparison 
8Better Bet Than BMY Stock: Pay Less Than Bristol-Myers Squibb To Get More From DUK, HCA   
9Better Bet Than BMY Stock: Pay Less Than Bristol-Myers Squibb To Get More From HCA, UTHR   
10Day 6 of Loss Streak for Bristol-Myers Squibb Stock with -12% Return (vs. -22% YTD) [7/31/2025]Notification 
11ARTICLES  
12BMY Stock Down -6.3% after 8-Day Loss Streak September 26th, 2025
13Is Bristol Myers Squibb Undervalued? September 22nd, 2025
14BMY Stock Down -12% after 6-Day Loss Streak August 1st, 2025
15Is It Time To Buy Bristol Myers Squibb Stock? April 28th, 2025
16How Will Bristol Myers Squibb Stock React To Its Upcoming Earnings? April 22nd, 2025
Title
0DASHBOARDS
1BMY Stock Down -6.3% after 8-Day Loss Streak
2Is Bristol Myers Squibb Undervalued?
3BMY Stock Down -12% after 6-Day Loss Streak
4Is It Time To Buy Bristol Myers Squibb Stock?
5How Will Bristol Myers Squibb Stock React To Its Upcoming Earnings?
6ARTICLES
7Bristol-Myers Squibb Earnings Notes
8How Low Can Bristol-Myers Squibb Stock Really Go?
9Day 8 of Loss Streak for Bristol-Myers Squibb Stock with -6.3% Return (vs. -22% YTD) [9/25/2025]
10Bristol-Myers Squibb vs Duke Energy: Which Is A Better Investment?
11Bristol-Myers Squibb vs Royalty Pharma: Which Is A Better Investment?
12Bristol-Myers Squibb vs Innoviva: Which Is A Better Investment?
13How Does Bristol-Myers Squibb Stock Stack Up Against Its Peers?
14Better Bet Than BMY Stock: Pay Less Than Bristol-Myers Squibb To Get More From DUK, HCA 
15Better Bet Than BMY Stock: Pay Less Than Bristol-Myers Squibb To Get More From HCA, UTHR 
16Day 6 of Loss Streak for Bristol-Myers Squibb Stock with -12% Return (vs. -22% YTD) [7/31/2025]

Trade Ideas

Select past ideas related to BMY. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		4.0%4.0%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.4%2.4%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		6.6%6.6%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		18.2%18.2%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		18.1%18.1%-8.0%
BMY_7312025_Dip_Buyer_FCFYield07312025BMYBristol-Myers SquibbDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		2.6%2.6%0.0%
BMY_4302024_Dip_Buyer_FCFYield04302024BMYBristol-Myers SquibbDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		22.7%19.9%-8.8%
BMY_10312023_Dip_Buyer_FCFYield10312023BMYBristol-Myers SquibbDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		-12.7%7.4%-20.4%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		4.0%4.0%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.4%2.4%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		6.6%6.6%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		18.2%18.2%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		18.1%18.1%-8.0%
BMY_7312025_Dip_Buyer_FCFYield07312025BMYBristol-Myers SquibbDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		2.6%2.6%0.0%
BMY_4302024_Dip_Buyer_FCFYield04302024BMYBristol-Myers SquibbDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		22.7%19.9%-8.8%
BMY_10312023_Dip_Buyer_FCFYield10312023BMYBristol-Myers SquibbDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		-12.7%7.4%-20.4%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1VICRVicor57.5%87.2%
2INBXInhibrx Biosciences53.8%272.0%
3CLBCore Laboratories48.7%-2.4%
4BALYBallys46.2%6.8%
5MOFGMidWestOne Financial43.2%39.2%
6NUVBNuvation Bio42.2%82.3%
7CLOVClover Health Investments41.0%21.3%
8CELCCelcuity36.6%442.2%
9WGOWinnebago Industries33.6%-12.7%
10GTXGarrett Motion33.3%91.3%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-45.4%8328.6%
2ITGRInteger-30.4%-45.0%
3METCRamaco Resources-23.8%244.9%
4WRLDWorld Acceptance-18.6%25.6%
5ASMAvino Silver & Gold Mines-18.2%450.5%
6SESSES AI-17.6%15.5%
7SMPLSimply Good Foods-17.5%-48.0%
8TNGXTango Therapeutics-17.0%142.6%
9OKLOOklo-16.7%540.8%
10LENZLENZ Therapeutics-16.4%10.7%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1WOLFWolfspeed1498.4%344.0%
2PRAXPraxis Precision Medicines253.2%126.1%
3NVTSNavitas Semiconductor116.1%294.1%
4SNDKSanDisk97.4% 
5UAMYUnited States Antimony90.3%578.5%
6GRALGRAIL85.2%400.8%
7BALYBallys82.9%6.8%
8ORKAOruka Therapeutics81.1%40.5%
9INBXInhibrx Biosciences79.9%272.0%
10CIFRCipher Mining77.2%345.3%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1VGVenture Global-35.7% 
2PMIPicard Medical-35.3%8328.6%
3SOCSable Offshore-33.7%-41.7%
4FWRDForward Air-28.9%-39.0%
5FLYFirefly Aerospace-28.5% 
6ITGRInteger-28.4%-45.0%
7USNAUsana Health Sciences-26.5%-42.0%
8HTZHertz Global-26.3%41.5%
9RCReady Capital-25.1%-50.3%
10ULHUniversal Logistics-24.8%-61.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1VICRVicor57.5%87.2%
2INBXInhibrx Biosciences53.8%272.0%
3CLBCore Laboratories48.7%-2.4%
4BALYBallys46.2%6.8%
5MOFGMidWestOne Financial43.2%39.2%
6NUVBNuvation Bio42.2%82.3%
7CLOVClover Health Investments41.0%21.3%
8CELCCelcuity36.6%442.2%
9WGOWinnebago Industries33.6%-12.7%
10GTXGarrett Motion33.3%91.3%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-45.4%8328.6%
2ITGRInteger-30.4%-45.0%
3METCRamaco Resources-23.8%244.9%
4WRLDWorld Acceptance-18.6%25.6%
5ASMAvino Silver & Gold Mines-18.2%450.5%
6SESSES AI-17.6%15.5%
7SMPLSimply Good Foods-17.5%-48.0%
8TNGXTango Therapeutics-17.0%142.6%
9OKLOOklo-16.7%540.8%
10LENZLENZ Therapeutics-16.4%10.7%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Bristol-Myers Squibb

Financials

BMYLLYJNJMRKZTSBGMMedian
NameBristol-.Eli LillyJohnson .Merck Zoetis BGM  
Mkt Price43.83825.45190.4087.49145.949.34116.72
Mkt Cap89.0741.2458.5219.665.0-219.6
Rev LTM47,63653,25892,14963,6169,385-53,258
Op Inc LTM7,87022,88224,14619,8213,520-19,821
FCF LTM13,086-5018,67914,7222,219-13,086
FCF 3Y Avg12,225-15617,81412,8991,869-12,225
CFO LTM14,31010,93824,20418,5342,929-14,310
CFO 3Y Avg13,4197,23023,20916,7662,549-13,419

Growth & Margins

BMYLLYJNJMRKZTSBGMMedian
NameBristol-.Eli LillyJohnson .Merck Zoetis BGM  
Rev Chg LTM4.6%36.8%5.1%1.8%5.3%-5.1%
Rev Chg 3Y Avg0.5%23.4%6.1%3.7%5.5%-5.5%
Rev Chg Q-5.6%37.6%6.8%-1.9%4.2%-4.2%
QoQ Delta Rev Chg LTM-1.4%8.7%1.7%-0.5%1.1%-1.1%
Op Mgn LTM16.5%43.0%26.2%31.2%37.5%-31.2%
Op Mgn 3Y Avg17.3%35.6%26.4%22.6%36.6%-26.4%
QoQ Delta Op Mgn LTM4.3%1.8%1.7%-0.8%0.5%-1.7%
CFO/Rev LTM30.0%20.5%26.3%29.1%31.2%-29.1%
CFO/Rev 3Y Avg28.9%17.8%26.4%27.2%28.7%-27.2%
FCF/Rev LTM27.5%-0.1%20.3%23.1%23.6%-23.1%
FCF/Rev 3Y Avg26.4%0.5%20.3%20.9%21.0%-20.9%

Valuation

BMYLLYJNJMRKZTSBGMMedian
NameBristol-.Eli LillyJohnson .Merck Zoetis BGM  
Mkt Cap89.0741.2458.5219.665.0-219.6
P/S1.913.95.03.56.9-5.0
P/EBIT11.041.714.210.718.4-14.2
P/E16.453.718.313.424.9-18.3
P/CFO6.267.818.911.822.2-18.9
Total Yield11.6%2.5%8.1%11.1%5.3%-8.1%
Dividend Yield5.5%0.7%2.7%3.7%1.3%-2.7%
FCF Yield 3Y Avg12.4%0.1%4.4%5.1%2.5%-4.4%
D/E0.60.10.10.20.1-0.1
Net D/E0.40.00.10.10.1-0.1

Returns

BMYLLYJNJMRKZTSBGMMedian
NameBristol-.Eli LillyJohnson .Merck Zoetis BGM  
1M Rtn0.6%11.3%7.8%9.8%3.0%-13.8%5.4%
3M Rtn-8.3%1.8%14.0%4.3%-4.1%-10.6%-1.1%
6M Rtn-6.0%-6.3%25.1%7.9%-4.6%-15.9%-5.3%
12M Rtn-13.1%-6.7%20.1%-14.3%-18.6%19.7%-9.9%
3Y Rtn-31.2%140.9%22.2%-2.1%-1.2%--1.2%
1M Excs Rtn-0.5%12.7%4.3%9.9%0.6%-11.1%2.4%
3M Excs Rtn-12.8%-3.9%9.1%-1.2%-9.5%-13.3%-6.7%
6M Excs Rtn-28.9%-29.2%2.2%-15.1%-27.5%-38.8%-28.2%
12M Excs Rtn-28.9%-24.6%4.2%-31.0%-38.1%5.2%-26.7%
3Y Excs Rtn-113.4%73.2%-57.1%-81.2%-82.2%--81.2%

Comparison Analyses

Financials

$ Mil | FY: 12/312025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q2
Period End3/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/20226/30/2022
Filing Date4/24/20252/12/202510/31/20247/26/20244/25/20242/13/202410/26/20237/27/20234/27/20232/14/202310/26/20227/27/2022
Key Financials Quarterly            
Total Revenue11,20112,34211,89212,20111,86511,47710,96611,22611,33711,40611,21811,887
Ebitda4,4772,5514,7734,403-8,5594,4544,8524,5735,4874,6745,0964,854
Operating Income3,4975102,1721,6911,5141,9031,9591,9012,4321,6942,0992,642
Net Income2,456721,2111,680-11,9111,7621,9282,0732,2622,0221,6061,421
EPS1.210.040.600.83-5.890.870.940.991.080.960.750.67
Key Financials TTM            
Total Revenue TTM47,63648,30047,43546,50945,53445,00644,93545,18745,84846,15946,73847,144
Ebitda TTM16,2043,1685,0715,1505,32019,36619,58619,83020,11119,22119,30719,423
Operating Income TTM7,8705,8877,2807,0677,2778,1957,9868,1268,8679,1049,7509,670
Net Income TTM5,419-8,948-7,258-6,541-6,1488,0258,2857,9637,3116,3276,6776,617
Growth Rates Quarterly            
Total Revenue Growth-5.6%7.5%8.4%8.7%4.7%0.6%-2.2%-5.6%-2.7%-4.8%-3.5%1.6%
EBITDA Growth152.3%-42.7%-1.6%-3.7%-256.0%-4.7%-4.8%-5.8%19.4%-1.8%-2.2%5.6%
Operating Income Growth131.0%-73.2%10.9%-11.0%-37.7%12.3%-6.7%-28.0%-8.9%-27.6%4.0%12.7%
Net Income Growth120.6%-95.9%-37.2%-19.0%-626.6%-12.9%20.0%45.9%77.0%-14.8%3.9%34.7%
Margins Quarterly            
EBITDA Margin40.0%20.7%40.1%36.1%-72.1%38.8%44.2%40.7%48.4%41.0%45.4%40.8%
Operating Income Margin31.2%4.1%18.3%13.9%12.8%16.6%17.9%16.9%21.5%14.9%18.7%22.2%
Net Income Margin21.9%0.6%10.2%13.8%-100.4%15.4%17.6%18.5%20.0%17.7%14.3%12.0%
Cash & Debt            
Total Cash11,78210,8598,0946,6539,67012,2807,6858,7309,2699,2539,02713,266
Total Debt51,23951,20051,40054,00457,40941,46439,26739,18639,37140,71740,11043,042
Net Debt / (Cash)39,45740,34143,30647,35147,73929,18431,58230,45630,10231,46431,08329,776
Cash Flows Quarterly            
FCF from Operations1,9544,4395,5912,3262,8344,2524,7511,8872,9703,3063,6872,261
Cash Flows TTM            
FCF from Operations TTM14,31015,19015,00314,16313,72413,86012,91411,85012,22413,06613,81715,396
Returns to Shareholders Quarterly            
Dividends1,2581,2181,2161,2171,2121,1601,1911,1971,1961,1451,1541,150
Share Repurchases-0-0-0-0-0-04,0009052502,416585-0
Return on Invested Capital (ROIC) Quarterly            
ROIC29.4%2.2%14.5%14.3%12.7%26.1%22.5%25.0%26.4%21.5%19.7%25.9%
Return on Invested Capital (ROIC) TTM            
ROIC TTM17.8%14.6%16.8%14.9%15.2%26.7%24.3%24.5%24.5%23.8%27.2%28.1%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Eliquis12,20611,78910,7629,1687,929
Opdivo9,0098,2497,5236,9927,204
Revlimid6,0979,97812,82112,1061,299
Orencia3,6013,4643,3063,1572,977
Pomalyst/Imnovid3,4413,4973,3323,070322
Yervoy2,2382,1312,0261,6821,489
Sprycel1,9302,1652,1172,1402,110
Other Growth products1,2111,092   
Reblozyl1,008717551274 
Abraxane1,0048111,1811,247166
Other Legacy products9621,162   
Opdualag6272520  
Abecma472388164  
Zeposia43425013412 
Breyanzi36418287  
Camzyos231240  
Sotyktu17080  
Augtyro100  
Cobenfy00   
Krazati00   
Inrebic  74555
Mature and other brands  2,2342,217 
Onureg  7317 
Empliciti   381357
Baraclude    555
Other Brands    1,674
Vidaza    58
Total45,00646,15946,38542,51826,145


Price Behavior

BMY Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta0.500.020.630.510.290.30
Up Beta-0.050.390.180.170.100.19
Down Beta-2.13-1.55-0.900.730.390.31
Up Capture15%37%84%32%22%6%
Bmk +ve Days13233574144420
Stock +ve Days9223262135370
Down Capture200%12%168%123%59%75%
Bmk -ve Days8192952107330
Stock -ve Days12203163115375

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date10152025
Short Interest: Shares Quantity30,358,285
Short Interest: % Change Since 930202515.2%
Average Daily Volume17,889,611
Days-to-Cover Short Interest1.70
Basic Shares Quantity2,031,000,000
Short % of Basic Shares1.5%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
7/31/2025-5.8%-2.5%2.0%
4/24/20250.3%3.4%-3.1%
2/6/2025-3.8%-6.0%2.3%
10/31/20245.9%5.0%12.5%
7/26/202411.4%6.4%6.3%
4/25/2024-8.5%-9.5%-15.0%
2/2/20240.1%0.1%4.6%
10/26/2023-6.4%-9.4%-12.1%
...
SUMMARY STATS   
# Positive121312
# Negative121112
Median Positive2.0%3.4%2.1%
Median Negative-3.4%-2.6%-3.2%
Max Positive11.4%6.8%12.5%
Max Negative-8.5%-9.5%-15.0%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025731202510-Q 6/30/2025
3312025424202510-Q 3/31/2025
12312024212202510-K 12/31/2024
93020241031202410-Q 9/30/2024
6302024726202410-Q 6/30/2024
3312024425202410-Q 3/31/2024
12312023213202410-K 12/31/2023
93020231026202310-Q 9/30/2023
6302023727202310-Q 6/30/2023
3312023427202310-Q 3/31/2023
12312022214202310-K 12/31/2022
93020221026202210-Q 9/30/2022
6302022727202210-Q 6/30/2022
3312022429202210-Q 3/31/2022
12312021209202210-K 12/31/2021
93020211027202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Elkins David VEVP, Chief Financial Officer9032025Sell47.3356,0002,650,4807,922,048Form
1Hickey BenjaminPresident, RayzeBio Org.5132025Sell38.01973,702 Form
2Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.4292025Buy47.584,250202,2153,973,572Form
3BOERNER CHRISTOPHER S.Chief Executive Officer2212025Buy55.052,000110,0965,759,452Form
4Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.2192025Buy54.841,823100,0003,506,058Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.